PET imaging of tumor glycolysis downstream of hexokinase through noninvasive measurement of pyruvate kinase M2

Science Translational Medicine

Volumn 7, Issue 310, 2015, Pages

  Witney, Timothy H ^a,c   James, Michelle L ^a,b   Shen, Bin ^a   Chang, Edwin ^a   Pohling, Christoph ^a   Arksey, Natasha ^a   Hoehne, Aileen ^a,d   Shuhendler, Adam ^a   Park, Jun Hyung ^a   Bodapati, Deepika ^a   Weber, Judith ^a   Gowrishankar, Gayatri ^a   Rao, Jianghong ^a   Chin, Frederick T ^a   Gambhir, Sanjiv Sam ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Pharmaceuticals GmbH 3B   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DASA 23 C 11; HEXOKINASE; PYRUVATE KINASE; PYRUVATE KINASE M2; TRACER; UNCLASSIFIED DRUG; CARBON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; HUMAN CELL; IMAGE DISPLAY; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; BRAIN TUMOR; ENZYMOLOGY; METABOLISM; SCINTISCANNING;

BRAIN NEOPLASMS; CARBON RADIOISOTOPES; GLYCOLYSIS; HEXOKINASE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PYRUVATE KINASE;

EID: 84945935560     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac6117     Document Type: Article

References (38)

1. R. A. Cairns, I. S. Harris, T. W. Mak, Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95 (2011).
2. O. Warburg, On the origin of cancer cells. Science 123, 309-314 (1956).
3. L. K. Boroughs, R. J. DeBerardinis, Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17, 351-359 (2015).
4. A. Carracedo, L C. Cantley, P. P. Pandolfi, Cancer metabolism: Fatty acid oxidation in the limelight. Nat. Rev. Cancer 13, 227-232 (2013).
5. R. A. Gatenby, R. J. Gillies, Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899 (2004).
6. N. Wong, J. De Melo, D. Tang, PKM2, a central point of regulation in cancer metabolism. Int. J. Cell Biol. 2013, 242513 (2013).
7. J. D. Dombrauckas, B. D. Santarsiero, A. D. Mesecar, Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44, 9417-9429 (2005).
8. S. Mazurek, Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43, 969-980 (2011).
9. B. Chaneton, E. Gottlieb, Rocking cell metabolism: Revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem. Sci. 37, 309-316 (2012).
10. E. Bailey, F. Stirpe, C. B. Taylor, Regulation of rat liver pyruvate kinase. The effect of preincubation, pH, copper ions, fructose 1, 6-diphosphate and dietary changes on enzyme activity. Biochem. J. 108, 427-436 (1968).
11. H. R. Christofk, M. G. Vander Heiden, N. Wu, J. M. Asara, L C Cantley, Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181-186 (2008).
12. M. B. Boxer, J.-k. Jiang, M. G. Vander Heiden, M.Shen, A. P. Skoumbourdis, N.Southall, H. Veith, W. Leister, C. P. Austin, H. W. Park, J. Inglese, L. C. Cantley, D. S. Auld, C.J.Thomas, Evaluation of substituted N, N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med. Chem. 53, 1048-1055 (2009).
13. W.J. Israelsen, T. L Dayton, S. M. Davidson, B. P. Fiske, A. M. Hosios, G. Bellinger, J. Li, Y. Yu, M. Sasaki, J. W. Horner, L. N. Burga, J. Xie, M. J. Jurczak, R. A. DePinho, C. B. Clish, T. Jacks, R. G. Kibbey, G. M. Wulf, D. Di Vizio, G. B. Mills, L. C. Cantley, M. G. Vander Heiden, PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155, 397-409 (2013).
14. D. Anastasiou, Y. Yu, W. J. Israelsen, J.-K. Jiang, M. B. Boxer, B. S. Hong, W.Tempel, S. Dimov, M. Shen, A. Jha, H. Yang, K. R. Mattaini, C. M. Metallo, B. P. Fiske, K. D. Courtney, S. Malstrom, T. M. Khan, C. Kung, A. P. Skoumbourdis, H. Veith, N. Southall, M. J. Walsh, K. R. Brimacombe, W. Leister, S. Y. Lunt, Z. R. Johnson, K. E. Yen, K. Kunii, S. M. Davidson, H. R. Christofk, C P. Austin, J. Inglese, M. H. Harris, J. M. Asara, G. Stephanopoulos, F. G. Salituro, S. Jin, L. Dang, D. S. Auld, H.-W. Park, L. C. Cantley, C. J. Thomas, M. G. Vander Heiden, Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8, 839-847 (2012).
15. M. Hidalgo, F. Amant, A. V. Biankin, E. Budinská, A. T. Byrne, C. Caldas, R. B. Clarke, S. de Jong, J. Jonkers, G. M. Mælandsmo, S. Roman-Roman, J. Seoane, L. Trusolino, A. Villanueva; EurOPDX Consortium, Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 4, 998-1013 (2014).
16. J.-K. Jiang, M. B. Boxer, M. G. Vander Heiden, M. Shen, A. P. Skoumbourdis, N. Southall, H. Veith, W. Leister, C. P. Austin, H. W. Park, J. Inglese, L. C. Cantley, D. S. Auld, C. J. Thomas, Evaluation of thieno[3, 2-b]pyrrole[3, 2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 20, 3387-3393 (2010).
17. L. Tong, Acetyl-coenzyme A carboxylase: Crucial metabolic enzyme and attractive target for drug discovery. Cell. Mol. Life Sci. 62, 1784-1803 (2005).
18. C. J. David, M. Chen, M. Assanah, P. Canoll, J. L. Manley, HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463, 364-368 (2010).
19. W. Luo, H. Hu, R. Chang, J. Zhong, M. Knabel, R. O'Meally, R. N. Cole, A. Pandey, G. L. Semenza, Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732-744 (2011).
20. L. Lv, D. Li, D. Zhao, R. Lin, Y. Chu, H. Zhang, Z. Zha, Y. Liu, Z. Li, Y. Xu, G. Wang, Y. Huang, Y. Xiong, K.-L. Guan, Q.-Y. Lei, Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 42, 719-730 (2011).
21. E. Eigenbrodt, M. Reinacher, U. Scheefers-Borchel, H. Scheefers, R. Friis, Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit. Rev. Oncog. 3, 91-115 (1992).
22. M.G. Vander Heiden, L. C. Cantley, C. B.Thompson, Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
23. K. Bluemlein, N.-M. Grüning, R. G. Feichtinger, H. Lehrach, B. Kofler, M. Ralser, No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2, 393-400 (2011).
24. H. R. Christofk, M. G. Vander Heiden, M. H. Harris, A. Ramanathan, R. E. Gerszten, R. Wei, M. D. Fleming, S. L. Schreiber, L. C. Cantley, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008).
25. K. Imamura, T. Tanaka, Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I. Electrophoretic studies. J. Biochem. 71, 1043-1051 (1972).
26. 18F-C-SNAT to established radiotracer imaging agents for the detection of tumor response to treatment. Clin. Cancer Res. 21, 3896-3905 (2015).
27. G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, L. Shankar, S. M. Larson, C. C. Sigman, R. L. Schilsky, D. C. Sullivan, Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res. 11, 2785-2808 (2005).
28. A. Sharma, P. Fidias, L. A. Hayman, S. L. Loomis, K. H. Taber, S. L. Aquino, Patterns of lymph-adenopathy in thoracic malignancies. Radiographics 24, 419-434 (2004).
29. M. E. Phelps, J. C. Mazziotta, Positron emission tomography: Human brain function and biochemistry. Science 228, 799-809 (1985).
30. 18F-FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging 40, 1025-1035 (2013).
31. 11C]methionine uptake in brain tumours: Initial results of a comparative study. Eur. J. Nucl. Med. 27, 542-549 (2000).
32. S. Venneti, M. P. Dunphy, H. Zhang, K. L. Pitter, P. Zanzonico, C. Campos, S. D. Carlin, G. La Rocca, S. Lyashchenko, K. Ploessl, D. Rohle, A. M. Omuro, J. R. Cross, C. W. Brennan, W. A. Weber, E. C. Holland, I. K. Mellinghoff, H. F. Kung, J. S. Lewis, C. B. Thompson, Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci. Transl. Med. 7, 274ra217 (2015).
33. - transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin. Cancer Res. 18, 5427-5437 (2012).
34. M. G. Vander Heiden, H. R. Christofk, E. Schuman, A. O. Subtelny, H. Sharfi, E. E. Harlow, J. Xian, L. C. Cantley, Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 79, 1118-1124 (2010).
35. M. J. Walsh, K. R. Brimacombe, H. Veith, J. M. Bougie, T. Daniel, W. Leister, L. C. Cantley, W. J. Israelsen, M. G. Vander Heiden, M. Shen, D. S. Auld, C. J. Thomas, M. B. Boxer, 2-Oxo-N-aryl-1, 2, 3, 4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 21, 6322-6327 (2011).
36. I. Park, J. Mukherjee, M. Ito, M. M. Chaumeil, L. E. Jalbert, K. Gaensler, S. M. Ronen, S. J. Nelson, R. O. Pieper, Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. Cancer Res. 74, 7115-7124 (2014).
37. M. S. Goldberg, P. A. Sharp, Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J. Exp. Med. 209, 217-224 (2012).
38. M. L. James, B. Shen, C. L. Zavaleta, C. H. Nielsen, C. Mesangeau, P. K. Vuppala, C. Chan, B. A. Avery, J. A. Fishback, R. R. Matsumoto, S. S. Gambhir, C. R. McCurdy, F. T. Chin, New positron emission tomography (PET) radioligand for imaging s-1 receptors in living subjects. J. Med. Chem. 55, 8272-8282 (2012).